Regneneron 4Q Revenues: $802.3 million (+31%) 4Q Earnings: $110.2 million (+14%) FY Revenues: $2.8 billion (+34%) FY Earnings: $348.1 million (-18%) Comments: EYLEA Injection sales increased 39% to $815 million in the quarter, with sales of $518 million in the U.S. and $297 million in rest of world. Bayer HealthCare commercializes EYLEA outside the U.S., of which Regeneron recognized $88 million after development expenses. In October 2014, the FDA approved EYLEA for the treatment of macular...